KRAS Market

NRAS, HRAS and KRAS Market by Target Indication, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions (North America, Europe, Asia-Pacific, and RoW): Industry Trends and Global Forecasts, 2021-2031

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    131

  • View Count
    12076

KRAS Market Overview

The NRAS, HRAS and KRAS market is estimated to be worth $73 million in 2021 and is expected to grow at CAGR of 53.6% during the forecast period. Close to 10 million fatalities reported in 2020 were observed to be associated with cancer, which is believed to be one of the leading causes of death, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed treatment, further leading to severe compromises with chances of survival of a patient. Moreover, post the onset of the COVID-19 pandemic, the treatment of cancer patients has become arduous, as patient visits are being cancelled by healthcare facilities in order to preserve resources and prevent patients from getting infected with SARS-CoV-2. Further, as per the National Cancer Institute, the delay in screening and treatment of cancer patients due to the COVID-19 pandemic is likely to result in 10,000 deaths, which could have been otherwise prevented, over the next decade. Specifically, in 2020, the global prevalence of human cancers was estimated to be 50.5 million; of this, majority of the cases were reported to be of breast cancer and lung cancer. Since a large share of the population remains affected with various oncological indications, cancer therapeutics continue to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry. 

Context of KRAS Market List of RAS Targeting Therapies in KRAS Market Market Landscape and Market Trends of KRAS Market

Given the complexities associated with conventional cancer treatment options, such as chemotherapy and radiation therapy, drug developers engaged in this domain have shifted their focus on the development of drugs against specific oncogenic mutations that are primarily responsible for the disease development and / or progression. It is worth mentioning that one such target (RAS), which was previously considered undruggable, was found to be associated with 30% of cancers in humans. Over the years, several drug candidates have been evaluated to target specific RAS mutated genes. In 2021, LUMAKRAS™ (sotorasib), a RAS targeting small molecule was approved by the USFDA for the treatment of metastatic non-small cell lung cancer in patients with KRAS G12C mutations. Given its high efficacy and good safety profile, significant efforts are being made to evaluate the potential of the aforementioned drug across multiple solid tumor indications, such as colorectal cancer. Presently, several companies (including big pharma players), independently or in collaboration with other stakeholders, are actively engaged in the development of RAS targeting therapies. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive market growth during the forecast period.

Key Companies in NRAS, HRAS and KRAS Market 

Examples of key companies engaged in NRAS, HRAS and KRAS market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, GlobeImmune, Jacobio Pharmaceuticals, Mirati Therapeutics, Novartis, Onconova Therapeutics, Targovax and Verastem Oncology. This market report includes an easily searchable excel database of all the companies developing RAS targeting therapies, worldwide.

Recent Developments in KRAS Market:

Several recent developments have taken place in the field of KRAS market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Verastem Oncology entered into a discovery and development collaboration with GenFleet Therapeutics with an aim to advance new programs targeting RAS pathway-driven cancers. 
  • In February 2023, Nested Therapeutics announced the nomination of first development candidate, a potential first-in-class kras inhibitor of the RAS/MAPK pathway. 
  • In January 2023, The Food and Drug Administration (FDA) granted accelerated approval to Tukysa® (tucatinib) in combination with trastuzumab for the treatment of adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer.
Product Competitiveness Analysis in KRAS Market Clinical Trial Analysis in KRAS Market Funding and Investment Analysis in KRAS Market

Scope of the Report

The ‘KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031, market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the KRAS market. Further, the market research reprot underlines an in-depth analysis of players engaged in the development of RAS targeting therapies. Amongst other elements, the market research report features:

  • A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I / II and phase I), type of molecule (biologic and small molecule), type of therapy (monotherapy and combination therapy), target therapeutic area (blood cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, pancreatic cancer, skin cancer, and undisclosed solid tumors), target gene (HRAS, KRAS and NRAS), line of treatment and route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), In addition, it presents details of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as year of establishment, employee count, and geographical presence.
  • An in-depth analysis of completed, ongoing and planned clinical trials of various RAS targeting therapies, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and regional distribution of trials.
  • An insightful competitive analysis, highlighting the key players engaged in KRAS market (on the basis of the strength of their respective development portfolios), along with information on several relevant parameters, such as company size and stage of development of lead molecules. 
  • Elaborate profiles of the key players engaged in offering RAS targeting therapies. Each profile features a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook. 
  • A detailed review of close to 1,600 peer-reviewed, scientific articles related to research on RAS targeting therapies, which have been published between January 2020 and April 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in KRAS market and impact factor of the journal).
  • An analysis of the recent partnerships inked between various players engaged in the development of RAS targeting therapies, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in KRAS market, during the period 2016-2021. 
  • A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by engaged in KRAS market, during the period 2016-2021. 
  • An elaborate discussion on the various commercialization strategies that have been adopted by drug developers engaged in KRAS market across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
Key Commercialization Strategies in KRAS Market Likely Growth Scenarios in KRAS Market Market Forecast and Opportunity Analysis in KRAS Market

The key objective of KRAS market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for KRAS market during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely annual treatment cost of RAS targeting therapies, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the market report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy, combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are RAS targeting therapies?

Answer: RAS (Rat Sarcoma) coded small GTPase is among the most frequently altered protein molecules in cancer cells. Novel treatment methods which hinder / inhibit the RAS alteration are termed as RAS targeting therapies.

Question 2: How big is the NRAS, HRAS and KRAS market?

Answer: The NRAS, HRAS and KRAS market size is estimated to be worth $73 million in 2021.

Question 3: What is the projected market growth of the NRAS, HRAS and KRAS market?

Answer: The NRAS, HRAS and KRAS market is expected to grow at compounded annual growth rate (CAGR) of 53.6% during the forecast period.

Question 4: Who are the leading companies developing NRAS, HRAS and KRAS inhibitors?

Answer: Examples of key companies engaged in developing drugs targeting NRAS, HRAS and KRAS (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, GlobeImmune, Jacobio Pharmaceuticals, Mirati Therapeutics, Novartis, Onconova Therapeutics, Targovax and Verastem Oncology.

Question 5: How many cancer cases with altered RAS protein have been reported in the last few years?

Answer: In 2020 alone, more than 3 million cases of RAS gene mutated cancer were reported.

Question 6: How many drugs are currently approved or under development by companies engaged in the NRAS, HRAS and KRAS market?

Answer: Over 85 NRAS, HRAS and KRAS drugs are currently approved or under development.

Question 7: How much money has been invested by stakeholders in the NRAS, HRAS and KRAS market?

Answer: Over USD 1.5 billion has been invested by stakeholders in the NRAS, HRAS and KRAS market, highlighting the growing interest in research and development in this field.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com